Allergologie Select最新文献

{"title":"Climate change in Switzerland: Impact on hazel, birch, and grass pollen on the basis of half a century of pollen records (1969 - 2018).","authors":"Thomas Frei","doi":"10.5414/ALX02180E","DOIUrl":"https://doi.org/10.5414/ALX02180E","url":null,"abstract":"<p><p>As indicated by the Intergovernmental Panel on Climate Change (IPCC), human activities are estimated to have caused ~ 1.0 °C of global warming above pre-industrial levels. The impact of this global warming is diverse and pertains also plant biology. The start of the pollen season as well as the observed quantities of pollen have been considered indicators of the impact of climate change. Switzerland has one of the longest pollen time series now - more than half a century. It has been tested whether the impact of climate change is robust by checking with this long time series of different pollen like hazel, birch, and grass as prominent representatives of triggers of hay fever. The results indicate that based on a time series of 50 years, the pollen seasons of hazel, birch, and grass started earlier as the temperature increased. Comparing the annual amount of pollen, a relevant increase is only observed for hazel. However, it must be considered that in the observed 50 years there was a land use change from grass land to built-up land due to the increase of population, and yet certain pollen counts increased considerably.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"4 ","pages":"69-75"},"PeriodicalIF":0.0,"publicationDate":"2020-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38495551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)^A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)^B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)^C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)^D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)^E, Österreichische Gesellschaft für Pneumologie (ÖGP)^F in co-operation with the German, Austrian, and Swiss ARIA groups^G, and the European Academy of Allergy and Clinical Immunology (EAACI)^H.","authors":"Ludger Klimek, Oliver Pfaar, Margitta Worm, Thomas Eiwegger, Jan Hagemann, Markus Ollert, Eva Untersmayr, Karin Hoffmann-Sommergruber, Alessandra Vultaggio, Ioana Agache, Sevim Bavbek, Apostolos Bossios, Ingrid Casper, Susan Chan, Alexia Chatzipetrou, Christian Vogelberg, Davide Firinu, Paula Kauppi, Antonios Kolios, Akash Kothari, Andrea Matucci, Oscar Palomares, Zsolt Szépfalusi, Wolfgang Pohl, Wolfram Hötzenecker, Alexander R Rosenkranz, Karl-Christian Bergmann, Thomas Bieber, Roland Buhl, Jeroen Buters, Ulf Darsow, Thomas Keil, Jörg Kleine-Tebbe, Susanne Lau, Marcus Maurer, Hans Merk, Ralph Mösges, Joachim Saloga, Petra Staubach, Uta Jappe, Klaus F Rabe, Uta Rabe, Claus Vogelmeier, Tilo Biedermann, Kirsten Jung, Wolfgang Schlenter, Johannes Ring, Adam Chaker, Wolfgang Wehrmann, Sven Becker, Laura Freudelsperger, Norbert Mülleneisen, Katja Nemat, Wolfgang Czech, Holger Wrede, Randolf Brehler, Thomas Fuchs, Peter-Valentin Tomazic, Werner Aberer, Antje-Henriette Fink-Wagner, Fritz Horak, Stefan Wöhrl, Verena Niederberger-Leppin, Isabella Pali-Schöll, Wolfgang Pohl, Regina Roller-Wirnsberger, Otto Spranger, Rudolf Valenta, Mübecell Akdis, Paolo M Matricardi, François Spertini, Nicolai Khaltaev, Jean-Pierre Michel, Larent Nicod, Peter Schmid-Grendelmeier, Marco Idzko, Eckard Hamelmann, Thilo Jakob, Thomas Werfel, Martin Wagenmann, Christian Taube, Erika Jensen-Jarolim, Stephanie Korn, Francois Hentges, Jürgen Schwarze, Liam O Mahony, Edward F Knol, Stefano Del Giacco, Tomás Chivato Pérez, Jean Bousquet, Anna Bedbrook, Torsten Zuberbier, Cezmi Akdis, Marek Jutel","doi":"10.5414/ALX02166E","DOIUrl":"10.5414/ALX02166E","url":null,"abstract":"<p><strong>Background: </strong>Since the beginning of the COVID-19 pandemic, the treatment of patients with allergic and atopy-associated diseases has faced major challenges. Recommendations for \"social distancing\" and the fear of patients becoming infected during a visit to a medical facility have led to a drastic decrease in personal doctor-patient contacts. This affects both acute care and treatment of the chronically ill. The immune response after SARS-CoV-2 infection is so far only insufficiently understood and could be altered in a favorable or unfavorable way by therapy with monoclonal antibodies. There is currently no evidence for an increased risk of a severe COVID-19 course in allergic patients. Many patients are under ongoing therapy with biologicals that inhibit type 2 immune responses via various mechanisms. There is uncertainty about possible immunological interactions and potential risks of these biologicals in the case of an infection with SARS-CoV-2.</p><p><strong>Materials and methods: </strong>A selective literature search was carried out in PubMed, Livivo, and the internet to cover the past 10 years (May 2010 - April 2020). Additionally, the current German-language publications were analyzed. Based on these data, the present position paper provides recommendations for the biological treatment of patients with allergic and atopy-associated diseases during the COVID-19 pandemic.</p><p><strong>Results: </strong>In order to maintain in-office consultation services, a safe treatment environment must be created that is adapted to the pandemic situation. To date, there is a lack of reliable study data on the care for patients with complex respiratory, atopic, and allergic diseases in times of an imminent infection risk from SARS-CoV-2. Type-2-dominant immune reactions, as they are frequently seen in allergic patients, could influence various phases of COVID-19, e.g., by slowing down the immune reactions. Theoretically, this could have an unfavorable effect in the early phase of a SARS-Cov-2 infection, but also a positive effect during a cytokine storm in the later phase of severe courses. However, since there is currently no evidence for this, all data from patients treated with a biological directed against type 2 immune reactions who develop COVID-19 should be collected in registries, and their disease courses documented in order to be able to provide experience-based instructions in the future.</p><p><strong>Conclusion: </strong>The use of biologicals for the treatment of bronchial asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and spontaneous urticaria should be continued as usual in patients without suspected infection or proven SARS-CoV-2 infection. If available, it is recommended to prefer a formulation for self-application and to offer telemedical monitoring. Treatment should aim at the best possible control of difficult-to-control allergic and atopic diseases using adequate rescue and add-on therapy an","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"4 ","pages":"53-68"},"PeriodicalIF":0.0,"publicationDate":"2020-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38368483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA: Position paper of the German ARIA Group^A in cooperation with the Austrian ARIA Group^B, the Swiss ARIA Group^C, German Society for Applied Allergology (AEDA)^D, German Society for Allergology and Clinical Immunology (DGAKI)^E, Society for Pediatric Allergology (GPA)^F in cooperation with AG Clinical Immunology, Allergology and Environmental Medicine of the DGHNO-KHC^G and the European Academy of Allergy and Clinical Immunology (EAACI)^H.","authors":"Ludger Klimek,&nbsp;Oliver Pfaar,&nbsp;Margitta Worm,&nbsp;Karl-Christian Bergmann,&nbsp;Thomas Bieber,&nbsp;Roland Buhl,&nbsp;Jeroen Buters,&nbsp;Ulf Darsow,&nbsp;Thomas Keil,&nbsp;Jörg Kleine-Tebbe,&nbsp;Susanne Lau,&nbsp;Marcus Maurer,&nbsp;Hans Merk,&nbsp;Ralph Mösges,&nbsp;Joachim Saloga,&nbsp;Petra Staubach,&nbsp;Petra Stute,&nbsp;Klaus Rabe,&nbsp;Uta Rabe,&nbsp;Claus Vogelmeier,&nbsp;Tilo Biedermann,&nbsp;Kirsten Jung,&nbsp;Wolfgang Schlenter,&nbsp;Johannes Ring,&nbsp;Adam Chaker,&nbsp;Wolfgang Wehrmann,&nbsp;Sven Becker,&nbsp;Norbert Mülleneisen,&nbsp;Katja Nemat,&nbsp;Wofgang Czech,&nbsp;Holger Wrede,&nbsp;Randolf Brehler,&nbsp;Thomas Fuchs,&nbsp;Peter-Valentin Tomazic,&nbsp;Werner Aberer,&nbsp;Antje Fink-Wagner,&nbsp;Friedrich Horak,&nbsp;Stefan Wöhrl,&nbsp;Verena Niederberger-Leppin,&nbsp;Isabella Pali-Schöll,&nbsp;Wolfgang Pohl,&nbsp;Regina Roller-Wirnsberger,&nbsp;Otto Spranger,&nbsp;Rudolf Valenta,&nbsp;Mübecell Akdis,&nbsp;Cezmi Akdis,&nbsp;Karin Hoffmann-Sommergruber,&nbsp;Marek Jutel,&nbsp;Paolo Matricardi,&nbsp;FranÇois Spertin,&nbsp;Nikolai Khaltaev,&nbsp;Jean-Pierre Michel,&nbsp;Laurent Nicod,&nbsp;Peter Schmid-Grendelmeier,&nbsp;Eckard Hamelmann,&nbsp;Thilo Jakob,&nbsp;Thomas Werfel,&nbsp;Martin Wagenmann,&nbsp;Christian Taube,&nbsp;Michael Gerstlauer,&nbsp;Christian Vogelberg,&nbsp;Jean Bousquet,&nbsp;Torsten Zuberbier","doi":"10.5414/ALX02147E","DOIUrl":"https://doi.org/10.5414/ALX02147E","url":null,"abstract":"<p><p>No abstract available.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"4 ","pages":"44-52"},"PeriodicalIF":0.0,"publicationDate":"2020-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304289/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38074536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics: Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) in collaboration with the German Society of Allergology (AeDA), German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Austrian Society for Allergology and Immunology (ÖGAI), and the Paul-Ehrlich Society for Chemotherapy (PEG).","authors":"Gerda Wurpts, Werner Aberer, Heinrich Dickel, Randolf Brehler, Thilo Jakob, Burkhard Kreft, Vera Mahler, Hans F Merk, Norbert Mülleneisen, Hagen Ott, Wolfgang Pfützner, Stefani Röseler, Franziska Ruëff, Helmut Sitter, Cord Sunderkötter, Axel Trautmann, Regina Treudler, Bettina Wedi, Margitta Worm, Knut Brockow","doi":"10.5414/ALX02104E","DOIUrl":"10.5414/ALX02104E","url":null,"abstract":"<p><p>This guideline on diagnostic procedures for suspected beta-lactam antibiotic (BLA) hypersensitivity was written by the German and Austrian professional associations for allergology, and the Paul-Ehrlich Society for Chemotherapy in a consensus procedure according to the criteria of the German Association of Scientific Medical Societies. BLA such as penicillins and cephalosporins represent the drug group that most frequently triggers drug allergies. However, the frequency of reports of suspected allergy in patient histories clearly exceeds the number of confirmed cases. The large number of suspected BLA allergies has a significant impact on, e.g., the quality of treatment received by the individual patient and the costs to society as a whole. Allergies to BLA are based on different immunological mechanisms and often manifest as maculopapular exanthema, as well as anaphylaxis; and there are also a number of less frequent special clinical manifestations of drug allergic reactions. All BLA have a beta-lactam ring. BLA are categorized into different classes: penicillins, cephalosporins, carbapenems, monobactams, and beta-lactamase inhibitors with different chemical structures. Knowledge of possible cross-reactivity is of considerable clinical significance. Whereas allergy to the common beta-lactam ring occurs in only a small percentage of all BLA allergic patients, cross-reactivity due to side chain similarities, such as aminopenicillins and aminocephalosporins, and even methoxyimino cephalosporins, are more common. However, the overall picture is complex and its elucidation may require further research. Diagnostic procedures used in BLA allergy are usually made up of four components: patient history, laboratory diagnostics, skin testing (which is particularly important), and drug provocation testing. The diagnostic approach - even in cases where the need to administer a BLA is acute - is guided by patient history and risk - benefit ratio in the individual case. Here again, further studies are required to extend the present state of knowledge. Performing allergy testing for suspected BLA hypersensitivity is urgently recommended not only in the interests of providing the patient with good medical care, but also due to the immense impact of putative BLA allergies on society as a whole.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"4 ","pages":"11-43"},"PeriodicalIF":0.0,"publicationDate":"2020-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38070191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"New\" inhalant plant allergens.","authors":"Stefani T M Röseler,&nbsp;Jens M Baron,&nbsp;Conny Höflich,&nbsp;Hans F Merk,&nbsp;Murat Bas,&nbsp;Henning Bier,&nbsp;Wolfgang Dott,&nbsp;Katharina Fietkau,&nbsp;Zuzanna Hajdu,&nbsp;Lorraine Kaiser,&nbsp;Thomas Kraus,&nbsp;Gottfried Laven,&nbsp;Silke Moll-Slodowy,&nbsp;Hans-Guido Mücke,&nbsp;Wolfgang Straff,&nbsp;Gerda Wurpts,&nbsp;Amir S Yazdi,&nbsp;Adam Chaker,&nbsp;Galina Balakirski","doi":"10.5414/ALX02066E","DOIUrl":"10.5414/ALX02066E","url":null,"abstract":"<p><p>Specific IgE measurements obtained from patients suffering from respiratory allergy (n = 952) show that, despite similar climatic conditions, there are clear regional differences in pollen sensitization between North Rhine-Westphalia and Bavaria. The data on sensitization levels and pollen concentration was taken from the research and development project Ufoplan 3710 61 228 of the German Environment Agency for North Rhine-Westphalia and Bavaria (2011 - 2014). Most poly-sensitized patients have already shown sensitization, both in the form of cross-reactivity and species-specific sensitization, to \"new\" pollen allergens, such as Bermuda grass and olive tree. These plants are currently not common in Germany, but may become considerably more widespread due to the increase in average yearly temperatures caused by the global warming. The other \"new\" aeroallergens discussed here are plants that can be found throughout Germany, such as nettle, cypress, and pine. Their current sensitization levels are higher than 8%; however, their clinical impact appears to be underestimated. For clinical practice it is important to identify when patients' symptoms are typically severe and which regional plants might be responsible for the patients' complaints in this period of time, as this affects further diagnostic strategy. Allergens having an immune effect can then be targeted by specific immunotherapies. The information on complaints of the patients should be regularly recorded in symptom diaries. Recording this information for at least 1 year may allow to discover a correlation between specific types of pollen and allergy symptoms.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"4 ","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2020-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37891477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ARIA guideline 2019: treatment of allergic rhinitis in the German health system.","authors":"Ludger Klimek,&nbsp;Claus Bachert,&nbsp;Oliver Pfaar,&nbsp;Sven Becker,&nbsp;Thomas Bieber,&nbsp;Randolph Brehler,&nbsp;Roland Buhl,&nbsp;Ingrid Casper,&nbsp;Adam Chaker,&nbsp;Wolfgang Czech,&nbsp;Jörg Fischer,&nbsp;Thomas Fuchs,&nbsp;Michael Gerstlauer,&nbsp;Karl Hörmann,&nbsp;Thilo Jakob,&nbsp;Kirsten Jung,&nbsp;Matthias V Kopp,&nbsp;Vera Mahler,&nbsp;Hans Merk,&nbsp;Norbert Mülleneisen,&nbsp;Katja Nemat,&nbsp;Uta Rabe,&nbsp;Johannes Ring,&nbsp;Joachim Saloga,&nbsp;Wolfgang Schlenter,&nbsp;Carsten Schmidt-Weber,&nbsp;Holger Seyfarth,&nbsp;Annette Sperl,&nbsp;Thomas Spindler,&nbsp;Petra Staubach,&nbsp;Sebastian Strieth,&nbsp;Regina Treudler,&nbsp;Christian Vogelberg,&nbsp;Andrea Wallrafen,&nbsp;Wolfgang Wehrmann,&nbsp;Holger Wrede,&nbsp;Torsten Zuberbier,&nbsp;Anna Bedbrook,&nbsp;Giorgio W Canonica,&nbsp;Victoria Cardona,&nbsp;Thomas B Casale,&nbsp;Wienczylawa Czarlewski,&nbsp;Wytske J Fokkens,&nbsp;Eckard Hamelmann,&nbsp;Marek Jutel,&nbsp;Désirée Larenas-Linnemann,&nbsp;Joaquim Mullol,&nbsp;Nikolaos G Papadopoulos,&nbsp;Sanna Toppila-Salmi,&nbsp;Thomas Werfel,&nbsp;Jean Bousquet","doi":"10.5414/ALX02120E","DOIUrl":"https://doi.org/10.5414/ALX02120E","url":null,"abstract":"<p><strong>Background: </strong>The number of patients affected by allergies is increasing worldwide. The resulting allergic diseases are leading to significant costs for health care and social systems. Integrated care pathways are needed to enable comprehensive care within the national health systems. The ARIA (Allergic Rhinitis and its Impact on Asthma) initiative develops internationally applicable guidelines for allergic respiratory diseases.</p><p><strong>Methods: </strong>ARIA serves to improve the care of patients with allergies and chronic respiratory diseases. In collaboration with other international initiatives, national associations and patient organizations in the field of allergies and respiratory diseases, real-life integrated care pathways have been developed for a digitally assisted, integrative, individualized treatment of allergic rhinitis (AR) with comorbid asthma. In the present work, these integrated care pathways have been adapted to the German situation and health system.</p><p><strong>Results: </strong>The present ICP (integrated care pathway) guideline covers key areas of the care of AR patients with and without asthma. It includes the views of patients and other healthcare providers.</p><p><strong>Discussion: </strong>A comprehensive ICP guideline can reflect real-life care better than traditional guideline models.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"3 1","pages":"22-50"},"PeriodicalIF":0.0,"publicationDate":"2019-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37740688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allergen immunotherapy phase II trials: Challenges in dose finding.","authors":"J Kleine-Tebbe,&nbsp;S Kaul,&nbsp;R Mösges","doi":"10.5414/ALX02033E","DOIUrl":"https://doi.org/10.5414/ALX02033E","url":null,"abstract":"<p><p>Phase II studies on allergen immunotherapy (AIT) should define the dose with the best balance between efficacy and safety (\"optimal dose\"). Their key role is based on dose selection for subsequent pivotal studies (phase III, field studies). Since products for AIT differ in composition and unit definitions, phase II trials are mandatory for new products and preparations being developed according to the German Therapy Allergen Ordinance (\"Therapie-Allergeneverordnung\", TAV) due to current EMA guidelines since 2009. The latter permit various in-vivo models and endpoints for phase II studies, e.g., AIT-induced changes in skin test, nasal, conjunctival or bronchial provocation, or in exposure chamber or field trials. Selection and graduation of the doses, minimization of placebo effects, and sufficient numbers of patients are a challenge. Effort, required time, and costs are important variables for the initiators of phase II trials. Risks are characterized by e.g., a) too small doses without relevant differences compared to placebo, b) missing true dose-response relationships, c) strong placebo effect and consequently small \"therapeutic window\", d) large heterogeneity and missing distinct differences (compared to placebo), e) too small effects in field studies due to low allergen exposure, f) missing dose-related increase (in case of too high doses). In the view of the Paul-Ehrlich-Institute, the unambiguous phase II trials with TAV products performed until today were not able to confirm the marketed doses for AIT. Regardless of the utilized model, more raw and single data should illustrate the individual outcome of AIT during phase II trials, facilitating an improved and more intuitive interpretation of the data (placebo effects? scattering?). In the medium term, evidence regarding AIT efficacy will considerably increase due to phase II trials as a prerequisite for subsequent phase III field studies. This affects all manufacturers offering AIT products in Germany and Europe.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"3 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2019-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37742213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TCM treatment of allergy induced by stainless steel implants for tibiofibular fracture: A case report.","authors":"Yansong Qi,&nbsp;Yi Ding,&nbsp;Baoge Liu,&nbsp;Yongsheng Xu","doi":"10.5414/ALX02095E","DOIUrl":"https://doi.org/10.5414/ALX02095E","url":null,"abstract":"<p><strong>Background: </strong>Metal allergy is frequently seen. Orthopedic metal implants, such as external fixators or other stainless implants, contain chromium, nickel, and molybdenum, which can cause type IV hypersensitivity.</p><p><strong>Case summary: </strong>A patient diagnosed with open comminuted tibiofibular fracture was treated with external fixation surgery, and she showed contact dermatitis and eczema-like symptoms 2 weeks postoperatively. She was then diagnosed as allergic to several metals by patch test and subsequently treated with traditional Chinese medicine (TCM), both orally and externally for 1 month. TCM treatment significantly alleviated the hypersensitive symptoms and made the patient bear the external fixator for 2 months until bone union.</p><p><strong>Conclusion: </strong>TCM therapy may be an effective treatment for external fixation-induced metal allergy and contact dermatitis.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"3 1","pages":"15-21"},"PeriodicalIF":0.0,"publicationDate":"2019-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37740686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allergen-specific IgE: comparison between skin prick test and serum assay in real life.","authors":"D Bignardi,&nbsp;P Comite,&nbsp;I Mori,&nbsp;F Ferrero,&nbsp;V Fontana,&nbsp;M Bruzzone,&nbsp;M Mussap,&nbsp;G Ciprandi","doi":"10.5414/ALX01891E","DOIUrl":"https://doi.org/10.5414/ALX01891E","url":null,"abstract":"<p><strong>Background: </strong>The most common sensitizing allergens in in the area of Liguria region (Northwestern Italy) are pollens, mainly <i>Parietaria</i> and cypress, house dust mites, i.e. <i>Dermatophagoides</i>, and pets. IgE assessment is a crucial step in allergy diagnosis. It may be performed by skin prick test (SPT) or serum IgE (sIgE) assay. Therefore, this study compared these two methods in a real-life setting.</p><p><strong>Methods: </strong>This retrospective study included 793 subjects, who were referred to the Allergy Department for respiratory allergy during 2014. Inclusion criteria were i) documented diagnosis of allergic rhinitis (AR), and/or allergic asthma, and/or allergic conjunctivitis. SPT and sIgE assay were performed for 5 allergens, such as <i>Dermatophagoides pteronyssinus</i> (D1), cat (E1), <i>Parietaria officinalis</i> (W19), cypress (T23), and dog (E5), as they are the most common in our geographic area.</p><p><strong>Results: </strong>Using a positive SPT result as the target condition, remarkably high and statistically significant values of AUC, ranging from 0.84 to 0.94, were found. On the basis of the Youden index the following optimal classification threshold values were also computed: D1 = 0.22, E1 = 0.26, W19 = 0.61, T23 = 0.25, E5 = 0.34. These values allowed to define a set of sensitivity/specifity estimates ranging from 0.75 to 0.93 and from 0.83 to 0.93, respectively.</p><p><strong>Conclusions: </strong>The present study shows that SPT and sIgE are two tests that are rather concordant, but with different sensitivity and specificity distinct for each allergen. In clinical practice, both tests should be used depending on clinical history features and obtained findings.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"3 1","pages":"9-14"},"PeriodicalIF":0.0,"publicationDate":"2019-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066680/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37740687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In search of clinically relevant parameters to monitor successful omalizumab therapy in allergic asthma.","authors":"M Probst,&nbsp;A Gogolka,&nbsp;M Krüll,&nbsp;O Noga","doi":"10.5414/ALX01377E","DOIUrl":"https://doi.org/10.5414/ALX01377E","url":null,"abstract":"<p><strong>Background: </strong>Omalizumab is approved as add-on therapy for the treatment of severe uncontrolled allergic asthma. Increase in quality of life and decrease of exacerbations and hospital admission, as well as immunmodulatory effects have been described with omalizumab therapy. However, to date there are few parameters to monitor success and to evaluate the individual advantage of this therapy for the patient. Furthermore, no reliable parameter to predict response to treatment exists so far. The aim of this study was to define an easily applicable parameter for response to treatment with omalizumab.</p><p><strong>Method: </strong>43 patients with allergic asthma were treated with omalizumab at a dose of at least 0,016 mg/kg/IgE every 4 weeks. Before, and 12 weeks after initiation of therapy, bodyplethysmography including airway resistance was performed. Efficacy of treatment was judged by the attending physician on the basis of a five point chart. Furthermore, a differential blood count was performed before, and 12 weeks after initiation of treatment. Total and specific IgE against all relevant antigens were determined before start of therapy.</p><p><strong>Results: </strong>Airway resistance in patients with response to treatment with omalizumab (responders) was significantly decreased in comparison to patients without clinical benefit (non-responder). The number of eosinophil granulocytes in the peripheral blood was decreased in both groups without significant difference. Response to therapy was associated with younger age and lower levels of specific IgE against the allergen with the highest sIgE-level (seasonal and perennial), but not with the sIgE level of the perennial allergens in general.</p><p><strong>Conclusion: </strong>Measurement of airway resistance might be an additional parameter for monitoring response to therapy with omalizumab. High specific IgE levels, for both perennial and concomitant seasonal allergens as well as increasing age, seem to predict less favorable treatment outcomes.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"2 1","pages":"49-55"},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881860/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37447935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}